Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma

References

• Qin C, Cao Q, Li P, et al. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Sci Rep. 2016;6:20089.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490.
   PubMed Web of Science ®Google Scholar
• Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev. 2005;31:536–545.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim S, Nam BH, et al. Primary tumor characteristics are important prognostic factors for sorafenib-treated patients with metastatic renal cell carcinoma: a retrospective multicenter study. Biomed Res Int. 2017;2017:9215930.
   PubMed Web of Science ®Google Scholar
• Ye DW, Zhang HL. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. Onco Targets Ther. 2014;7:925–935.
   PubMed Web of Science ®Google Scholar
• Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011;16:14–22.
   PubMed Web of Science ®Google Scholar
• Procopio G, Derosa L, Gernone A, et al. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol. 2014;10:1741–1750.
   PubMed Web of Science ®Google Scholar
• Sheng X, Chi Z, Cui C, et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016;7:27044–27054.
   PubMedGoogle Scholar
• Mai H, Huang J, Zhang Y, et al. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. Oncotarget. 2017;8:43458–43469.
   PubMedGoogle Scholar
• Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011;16:45–50.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. JCO. 2009;27:3312–3318.
   PubMed Web of Science ®Google Scholar
• Rini B, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012;118:6152–6161.
   PubMed Web of Science ®Google Scholar
• Krokidis ME, Kitrou P, Spiliopoulos S, et al. Image-guided minimally invasive treatment for small renal cell carcinoma. Insights Imaging. 2018;9:385–390.
   PubMed Web of Science ®Google Scholar
• Kapoor A, Wang Y, Dishan B, et al. Update on cryoablation for treatment of small renal mass: oncologic control, renal function preservation, and rate of complications. Curr Urol Rep. 2014;15:396.
   PubMed Web of Science ®Google Scholar
• Aoun HD, Littrup PJ, Jaber M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol. 2017;28:1363–1370.
   PubMed Web of Science ®Google Scholar
• Lalloue F, Ruffion A, Valette PJ, et al. Cryotherapy percutaneous for renal tumors: our center's beginning experience. Prog Urol. 2016;26:310–318.
   PubMed Web of Science ®Google Scholar
• Pal SK, Vogelzang NJ. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2013;11:146–155.
   PubMedGoogle Scholar
• Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol. 2012;53:217–228. PubMed PMID: 22536463; PubMed Central PMCID: PMCPMC3332131.
   PubMedGoogle Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015;13:151–159. FebPubMed PMID: 25691606.
   PubMedGoogle Scholar
• Tan X, Liu Y, Hou J, et al. Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Ther. 2015;8:313–321.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Qin XJ, Wang HK, et al. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget. 2015;6:36870–36883.
   PubMedGoogle Scholar
• Chang X, Wang Y, Yu HP, et al. CT-guided percutaneous cryoablation for palliative therapy of gastric cancer liver metastases. Cryobiology. 2018;82:43–48.
   PubMed Web of Science ®Google Scholar
• Song KD. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol. 2016;22:509–515.
   PubMed Web of Science ®Google Scholar
• Gao W, Guo Z, Shu S, et al. The application effect of percutaneous cryoablation for the stage IIIB/IV advanced non-small-cell lung cancer after the failure of chemoradiotherapy. Asian J Surg. 2018;pii:S1015-9584;30507–90507.
   Google Scholar
• Lin M, Liang SZ, Wang XH, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. 2017;65:880–887.
   PubMed Web of Science ®Google Scholar
• Liang X, Yang XL, Guo Z. Effect on cryoablation of high-risk and locally recurrent prostate cancer: a Meta-analysis. Zhonghua Yi Xue Za Zhi. 2017;97:1975–1980.
   PubMedGoogle Scholar
• Li Z, Fu Y, Li Q, et al. Cryoablation plus chemotherapy in colorectal cancer patients with liver metastases. Tumour Biol. 2014;35:10841–10848.
   PubMedGoogle Scholar
• Yang Y, Lu Y, Wang C, et al. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159–169.
   PubMed Web of Science ®Google Scholar
• Ni H, Yang M, Guo Z, et al. Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin J Cancer Res. 2011;23:188–193.
   PubMed Web of Science ®Google Scholar
• Wang C, Lu Y, Wang H, et al. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;4:188–196.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Secomb TW. Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer. 2017;17:738–750.
   PubMed Web of Science ®Google Scholar